Details of the Drug Combinations

General Information of This Drug (ID: DMFDQ3I)

• Drug Name: Daptomycin (DMFDQ3I)
• Synonyms: Dapcin; Daptomicina; Daptomycine; Daptomycinum; LY 146032; LY-146032; LY146032; (2S)-daptomycin; 103060-53-3; C72H101N17O26; Cidecin; Cubicin; DAPTOMYCIN; CHEBI:600103; N-decanoyl-L-tryptophyl-L-asparaginyl-N-[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontan-30-yl]-L-alpha-asparagine; SCHEMBL28102

Indication

Bacterial infection; ICD 11: 1A00-1C4Z; Status: Approved [1]; Skin infection; ICD 11: 1F28-1G0Z; Status: Investigative [2]

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Rifampicin + Daptomycin	DCPGIQB	Rifampicin	Drug Interactions	[3]
Daptomycin + Fosfomycin	DCZEPZT	Fosfomycin	Staph Aureus Methicillin Resistant Bacteremia	[4]
Vancomycin + Daptomycin	DCIIXKY	Vancomycin	Bacteremia	[5]
Linezolid + Daptomycin	DC6263U	Linezolid	Health Care Associated Pneumonia	[6]

References

• [1] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [2] Daptomycin FDA Label
• [3] ClinicalTrials.gov (NCT02097953) Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
• [4] ClinicalTrials.gov (NCT01898338) Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia
• [5] ClinicalTrials.gov (NCT02208063) A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
• [6] ClinicalTrials.gov (NCT01734694) Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients